Prodrugs: Design and clinical applications

Nature Reviews Drug Discovery

Volumn 7, Issue 3, 2008, Pages 255-270

  Rautio, Jarkko ^a   Kumpulainen, Hanna ^a   Heimbach, Tycho ^b   Oliyai, Reza ^c   Oh, Dooman ^d   Järvinen, Tomi ^a   Savolainen, Jouko ^e  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b NOVARTIS PHARMA AG   (Switzerland)

^c GILEAD SCIENCES   (United States)

^d AMGEN INC   (United States)

^e Fennopharma Ltd   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 3 (3,4 DICHLOROBENZYLOXY) 6 FLUOROBICYCLO[3.1.0]HEXANE 2,6 DICARBOXYLIC ACID; ADEFOVIR DIPIVOXIL; AMPRENAVIR; AMPRENAVIR PHOSPHATE; BAMBUTEROL; CAPECITABINE; DIPIVEFRINE; ENALAPRIL; ESTRAMUSTINE; FAMCICLOVIR; FLUCONAZOLE; FLUDARABINE PHOSPHATE; FOSFLUCONAZOLE; FOSPHENYTOIN SODIUM; GABAPENTIN; IRINOTECAN; LATANOPROST; LEVODOPA; MIDODRINE; MIPROXIFENE PHOSPHATE; OSELTAMIVIR; OXEOL; PIVAMPICILLIN; PROCIF; PRODRUG; SIMVASTATIN; SULINDAC; TAZAROTENE; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALACICLOVIR; VALGANCICLOVIR; XIMELAGATRAN;

BLOOD BRAIN BARRIER; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DESIGN; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; EPILEPSY; EYE IRRITATION; GLAUCOMA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; IN VIVO STUDY; LIPOPHILICITY; LIVER TOXICITY; MEMBRANE PERMEABILITY; NEOPLASM; NEUROPATHIC PAIN; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RESTLESS LEGS SYNDROME; REVIEW; SKIN DISEASE; SKIN IRRITATION; UNSPECIFIED SIDE EFFECT;

ABSORPTION; ADMINISTRATION, TOPICAL; ANIMALS; BIOLOGICAL AVAILABILITY; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; PARENTERAL NUTRITION; PRODRUGS;

EID: 40149088986     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2468     Document Type: Review

References (188)